Creative Biolabs has expanded its specialized antibody portfolio targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1. The expansion addresses a critical need in human retrovirus research, where access to well-characterized reagents can accelerate studies of viral entry, epitope recognition, immune responses, and diagnostic assay development. The portfolio now includes antibodies against gp140 for HIV-1, gp36 for HIV-2, and gag p19 for HTLV-1, offering researchers additional options for investigating these clinically significant pathogens.
The addition of an anti-gp140 HIV-1 antibody fills a gap in envelope biology research. The gp140 protein, an uncleaved ectodomain of the HIV-1 envelope glycoprotein, is a primary target for broadly neutralizing antibodies and vaccine design. By providing a reagent that specifically recognizes this protein, Creative Biolabs enables more precise studies of HIV-1 envelope biology, antigen recognition, and related assay development. This is particularly important given the ongoing challenge of developing an effective HIV-1 vaccine and the need to understand how the virus evades immune responses.
While HIV-1 accounts for the majority of global infections, HIV-2 presents unique clinical challenges due to its distinct genetic makeup and different disease progression rates. Because gp36 is an HIV-2 envelope-associated antigen, antibodies targeting gp36 can be useful research tools for studying antigen recognition, cross-reactivity, and the development and evaluation of HIV-2-focused assay concepts. The availability of such reagents is essential for differentiating between HIV-1 and HIV-2 infections and for understanding the unique pathogenesis of HIV-2, which is often understudied relative to its more prevalent counterpart.
Beyond HIV, the human T-cell lymphotropic virus type 1 (HTLV-1) represents another significant retroviral threat, being the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy. HTLV-1 gag p19 is a viral core protein commonly investigated in studies of HTLV-1 biology, viral protein expression, and immune recognition. Creative Biolabs' anti-HTLV-1 gag p19 antibody is intended for research applications such as Western blot, ELISA, and immunohistochemistry, supporting research into HTLV-1 pathogenesis and related virology questions. This antibody provides a valuable tool for researchers studying the mechanisms by which HTLV-1 establishes persistent infection and leads to severe diseases in a subset of infected individuals.
The implications of this expanded portfolio extend beyond basic research. Reliable antibodies are foundational for diagnostic assay development, and the ability to distinguish between different retroviral proteins is crucial for accurate detection and surveillance. Furthermore, as the scientific community continues to pursue vaccines and therapeutics for HIV and HTLV-1, having access to well-validated research reagents can streamline preclinical studies and improve reproducibility. Creative Biolabs' commitment to providing these tools supports the broader effort to combat retroviral diseases.
"Retrovirus research often depends on reagents that distinguish specific viral proteins and support different experimental formats," said a senior scientist at Creative Biolabs. "By expanding antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, we aim to give researchers additional options for studying viral proteins, antigen recognition, and assay development." This expansion reflects the company's ongoing dedication to advancing virology and infectious disease research. For more information about the complete range of retrovirus-targeted antibodies and custom services, visit https://www.antibody-creativebiolabs.com/.
For research use only. Not for use in diagnostic or therapeutic procedures.
